Sofinnova Partners, a European venture capital firm specialized in Life Sciences, has just launched BiovelocITA, the first Italian accelerator dedicated to biotech companies.
Sofinnova and a restricted group of investors will also provide €6m to the accelerator over the next years of operations.
Co-founded and managed by Silvano Spinelli, Chairman, and Gabriella Camboni, CEO, who founded EOS which they sold in 2013 to Clovis Oncology for $470 million, BiovelocITA brings together scientists, entrepreneurs and investors to accelerate to proof of concept promising research projects and transform them into biotech companies.
The accelerator has already signed its first strategic partnership with TTFactor, the tech-transfer company managing the intellectual property portfolio of three leading Italian Research Institutes, IFOM (the FIRC Institute of Molecular Oncology), IEO (Istituto Europeo di Oncologia, IRCCS), and Centro Cardiologico Monzino, IRCCS.
More than ten biotech projects are currently under study from TTFactor and other sources, and this agreement will broaden BiovelocITA’s projects’ sourcing capabilities.
FinSMEs
16/11/2015